Durect Signs Deal With Zogenix For Long-Acting Antipsychotic
This article was originally published in The Pink Sheet Daily
Executive Summary
Durect moves its business plan forward by inking a development deal with Zogenix for a once-monthly formulation of risperidone.
You may also be interested in...
Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects
Pfizer's abuse-deterrent, extended-release form of pain drug oxycodone faces legal, regulatory and manufacturing challenges.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.